BioSpace News Archive

Bellicum Pharmaceuticals, Inc. today announced that an abstract on early results from a Phase 1 clinical trial for BPX-601, its lead GoCAR-T ® product candidate, has been accepted for poster presentation at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU).

iSpecimen Inc. today announced that Tracy Curley, CEO of iSpecimen, will participate in the Healthcare IT Virtual Conference hosted by Maxim Group and M-Vest on Wednesday, January 25, 2023.

Zhongchao Inc. today announced that Zhongxin Medical Technology Co., Ltd. (“Zhongxin”), one of the China operating entities of which the Company consolidates the financial results with through certain contractual arrangements, launched the Medication Management Assistance Mini Program on WeChat.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Zymeworks Inc. (Nasdaq: ZYME) today announced tolerability and efficacy results, including the first overall survival (OS) data, from a Phase 2 trial examining zanidatamab, an investigational HER2-targeted bispecific antibody, in combination with chemotherapy, in first-line patients with HER2-expressing metastatic gastroesophageal adenocarcinoma (mGEA).

Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced the publication of preclinical proof-of-concept data for its gene therapy candidate for Fabry disease, FLT190, in the Nature journal Gene Therapy.

Vor Bio announced that clinical data from the first patient treated in VBP101, its Phase 1/2a multicenter, open-label, first-in-human study of trem-cel in patients with acute myeloid leukemia has been accepted as a late-breaking poster presentation at the 2023 Tandem Meetings, the Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, taking place February 15-19 in Orlando, Florida.

SAB Biotherapeutics announced that Eddie Sullivan, PhD, co-founder, President and CEO of SAB Biotherapeutics, will present at the 2023 BIO CEO & Investor Conference on Monday, February 6 at 11:15am ET.

Aprea Therapeutics, Inc. announced that it will participate in the 6th Annual DDR Inhibitors Summit, held in Boston, Massachusetts from January 24 – January 26, 2023.

Outlook Therapeutics, Inc. announced the appointments of Surendra Sharma, MD, as Senior Vice President, Medical Affairs, and Glen Olsheim as Executive Director, Commercial Excellence.

Daxor Corporation, the global leader in blood volume measurement technology, announces joining the Heart Failure Society of America as a corporate member to collaborate and deepen engagement with leaders in the field of heart failure.